Testing Compound Kushen injection for advanced colon cancer survival
Part of Cancer, Digestive system clinical trials.
This trial studies whether Compound Kushen injection can improve survival in people with advanced colorectal cancer. It’s aimed at people starting first-line treatment, and only includes certain cancer and health situations to keep results clear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have advanced colorectal cancer confirmed by pathology or cytology
- Start first-line (first) treatment for your cancer
- Be age 18 or older, and able to take part in follow-up visits
- Your general health must be good enough (ECOG 0 to 2) and you expect to live at least 3 months
- Scans/tests must show at least one measurable tumor spot
- Not have certain exclusions (pregnancy/breastfeeding, other cancers, certain immune therapy/radiation recently, or drug allergies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
Hear when a new Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.